An addition compound obtained by combining equimolar amounts of trametinib and dimethyl sulfoxide. Used for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment.
Stars
This entity has been manually annotated by the ChEBI Team.
trametinib dimethyl sulfoxide
(CHEBI:75991)
has part
dimethyl sulfoxide
(CHEBI:28262)
trametinib dimethyl sulfoxide
(CHEBI:75991)
has part
trametinib
(CHEBI:75998)
trametinib dimethyl sulfoxide
(CHEBI:75991)
has role
antineoplastic agent
(CHEBI:35610)
trametinib dimethyl sulfoxide
(CHEBI:75991)
has role
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
(CHEBI:79091)
trametinib dimethyl sulfoxide
(CHEBI:75991)
is a
addition compound
(CHEBI:35504)